Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ProTip Medical Closes USD 4.7 (EUR 3.8) Million Financing Round

Published: Tuesday, November 27, 2012
Last Updated: Tuesday, November 27, 2012
Bookmark and Share
Funds will advance clinical development of ProTip’s ENTegral™, world’s first permanent implant to replace the larynx in patients who have undergone a total laryngectomy.

ProTip SA has announced a USD 4.7 (EUR 3.8) million Series C financing round. The round was led by new VC investor Seventure, along with existing investors including Fonds Lorrain des Materiaux (FLM), the Berchet family-office, Alsace Amorcage and other private investors.

ProTip will use the funding to complete the company’s first human clinical trial of its ENTegral™ device, the world’s first permanent implant to replace the larynx in patients who have undergone a total laryngectomy.

It will also launch wider trials with the aim of bringing the implant to market. Since inception, ProTip has raised a total of EUR 6.8 million and has managed its development closely in line with its business plan.

"We are extremely pleased to welcome Seventure as a new partner,” said Maurice Berenger, CEO of ProTip. “More than mere financial resources, Seventure brings us its expertise and a conclusive track record as an experienced medical device investor.”

“There is currently no available solution for laryngectomized patients. ProTip’s ENTegral™ is designed to allow patients to go back to a normal, unimpaired social life,” added Berenger. “This Series C cash infusion will enable ProTip to move forward with this breakthrough medical device."

“We have been particularly attracted by the quality of the product portfolio dedicated to ear, nose and throat (ENT) applications, a medical sector where very few major innovations have come out these last few years,” said Emmanuel Fiessinger, general partner at Seventure.

Fiessinger continued, “The team has very high level financial and academic partners committed to this project, including a very strong public-private alliance, and this definitively convinced Seventure to support this company.”

“To have Seventure on board in this exciting venture is a further endorsement of the quality of the company,” said Laurent Bocahut, investment manager at FLM and member of ProTip’s supervisory board.

Bocahut continued, “With this successful round, ProTip is in an excellent position to become a market leader in the field of laryngology. This great achievement illustrates the quality and proficiency of ProTip’s operational team.”

“Today, there is no available treatment that alleviates the need for a definitive tracheotomy for patients having undergone total laryngectomy,” said Christian Debry, MD, PhD, head of ENT department at Strasbourg Teaching Hospital and co-founder of ProTip.

Debry continued, “The ENTegral implant aims to restore respiration through natural ways and to give laryngectomized patients access to a much better life.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Advanced Lymphoma in Remission After T-Cell Therapy
63% of trial participants who recieved two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission.
New Treatment for Immune Cancers
Clinical trial shows new drug holds promise for treating advanced mastocytosis.
Sickle Cell Gene Therapy Passes Test
Researchers found a precision-engineered gene therapy virus reduced sickle-induced red-cell damage in mice with sickle cell disease.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Inovio Launches Zika Vaccine Trial
Inovio launches Zika vaccine trial in midst of Puerto Rico epidemic to explore early signals of vaccine efficacy.
Vitamin C May Boost Leukemia Treatment
Studies show that supplementing an epigenetic cancer drug with vitamin C enhanced the drug's effectiveness.
New Hope for Zika Treatment Found in Large-Scale Screen of Existing Drugs
Johns Hopkins researchers join collaborative group to screen 6,000 existing drugs in hopes of finding treatments for Zika Virus infection
FINCH Filgotinib Phase 3 Program Initiated
Galapagos NV reports the initiation of the FINCH global Phase 3 program in rheumatoid arthritis patient populations.
Stem Cell Therapy Heals Injured Mouse Brain
A team of researchers has developed a therapeutic technique that dramatically increases the production of nerve cells in mice with stroke-induced brain damage.
Zika Vaccine Testing in Humans
The NAAID has initiated a clinical trail of a vaccine candidate for the prevention of the Zika virus infection.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!